Sponsored by AstraZeneca, the PACIFC study was a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study of MEDI14736 (durvalumab) as Sequential Therapy in Patients with Locally advanced, unresectable non-small cell lung cancer...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
